Measles control - Can measles virus inhibitors make a difference?

Current Opinion in Investigational Drugs

Volumn 10, Issue 8, 2009, Pages 811-820

  Plemper, Richard K ^a   Snyder, James P ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Antiviral; Drug; Eradication; Measles; Vaccine; Virus

Indexed keywords

5 ETHYNYL 1 BETA DEXTRO RIBOFURANOSYLIMIDAZOLE 4 CARBOXAMIDE; 5' LUORO 5' DEOXYARISTEROMYCIN; 5' NOR CARBOCYCLIC ADENOSINE DERIVATIVE; ANTIBIOTIC AS 48; ANTIVIRUS AGENT; AS 136A; IMMUNOGLOBULIN; ISOQUINOLINE DERIVATIVE; ISOTHIAZOLE DERIVATIVE; MEASLES VACCINE; MYCOPHENOLIC ACID; NATURAL PRODUCT; NEPLANOCIN A; NORARISTEROMYCIN DERIVATIVE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA2A; RIBAVIRIN; SPARFOSIC ACID; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL FEATURE; DISEASE ASSOCIATION; ERADICATION THERAPY; FEAR; GEOGRAPHIC DISTRIBUTION; HEMOLYTIC ANEMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MEASLES; MEASLES VIRUS; MORBIDITY; MORTALITY; PATHOGENESIS; REVIEW; UNITED KINGDOM; VIRUS HEPATITIS; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DISEASE OUTBREAKS; HUMANS; MEASLES; MEASLES VACCINE; MEASLES VIRUS;

EID: 68649087833     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Lamb RA, Parks GD: Paramyxoviridae: The viruses and their replication. In: Fields Virology, 1. Knipe DM, Howley PM (Eds), Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, PA, USA (2007):1449-1496.
2. Moss WJ, Griffin DE: Global measles elimination. Nat Rev Microbiol (2006) 4(12):900-908. • An excellent overview of recent progress toward the control of MV.
3. Griffin DE: Measles virus. In: Fields Virology, 1. Knipe DM, Howley PM (Eds), Wolters Kluwer/Lippincott Williams & Wilkins, Philadelphia, PA, USA (2007):1551-1585.
4. Hethcote HW: The mathematics of infectious disease. SIAM Review (2000) 42(4):599-653.
5. Black FL: Measles endemicity in insular populations: Critical community size and its evolutionary implication. J Theor Biol (1966) 11(2):207-211.
6. Keeling MJ: Modelling the persistence of measles. Trends Microbiol (1997) 5(12):513-518.
7. Compans RW, Mountcastle WE, Choppin PW: The sense of the helix of paramyxovirus nucleocapsids. J Mol Biol (1972) 65(1):167-169.
8. Tatsuo H, Ono N, Tanaka K, Yanagi Y: SLAM (CDw150) is a cellular receptor for measles virus. Nature (2000) 406 (6798): 893-897. • The first identification of SLAM as a receptor for MV isolates.
9. Tatsuo H, Ono N, Yanagi Y: Morbilliviruses use signaling lymphocyte activation molecules (CD150) as cellular receptors. J Virol (2001) 75(13):5842-5850.
10. Naniche D, Varior-Krishnan G, Cervoni F, Wild TF, Rossi B, Rabourdin-Combe C, Gerlier D: Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus. J Virol (1993) 67(10):6025-6032.
11. Manchester M, Eto DS, Valsamakis A, Liton PB, Fernandez-Muñoz R, Rota PA, Bellini WJ, Forthal DN, Oldstone MB: Clinical isolates of measles virus use CD46 as a cellular receptor. J Virol (2000) 74(9):3967-3974.
12. Dorig RE, Marcil A, Chopra A, Richardson CD: The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell (1993) 75(2):295-305.
13. Rima BK, Duprex WP: The measles virus replication cycle Curr Top Microbiol Immunol (2009) 329:77-102.
14. Sidhu MS, Chan J, Kaelin K, Spielhofer P, Radecke F, Schneider H, Masurekar M, Dowling PC, Billeter MA, Udem SA: Rescue of synthetic measles virus minireplicons: Measles genomic termini direct efficient expression and propagation of a reporter gene. Virology (1995) 208(2):800- 807.
15. de Swart RL: The pathogenesis of measles revisited. Pediatr Infect Dis J (2008) 27 (10 Suppl) :S84-S88.
16. von Messling V, Milosevic D, Cattaneo R: Tropism illuminated: Lymphocyte-based pathways blazed by lethal morbillivirus through the host immune system. Proc Natl Acad Sci USA (2004) 101(39):14216-14221.
17. de Swart RL, Ludlow M, de Witte L, Yanagi Y, van Amerongen G, McQuaid S, Yüksel S, Geijtenbeek TB, Duprex WP, Osterhaus AD: Predominant infection of CD150+ lymphocytes and dendritic cells during measles virus infection of macaques. PLoS Pathog (2007) 3(11):e178. • Identification of predominant infection of lymphoid cells in a nonhuman primate model.
18. Epidemiology and Prevention of Vaccine-Preventable Diseases. 11th edition. Public Health Foundation, Washington, DC, USA (2008).
19. Hilleman MR: Current overview of the pathogenesis and prophylaxis of measles with focus on practical implications. Vaccine (2001) 20 (5-6):651-665.
20. Nasr JT, Andriola MR, Coyle PK: ADEM: Literature review and case report of acute psychosis presentation. Pediatr Neurol (2000) 22(1):8-18.
21. Rima BK, Duprex WP: Morbilliviruses and human disease. J Pathol (2006) 208(2):199-214. • Comprehensive review of diseases that have been associated with MV.
22. Centers for Disease Control and Prevention (CDC): Progress in global measles control and mortality reduction, 2000-2007. MMWR Morb Mortal Wkly Rep (2008) 57(48):1303-1306.
23. Rosenau BJ, Schur PH: Association of measles virus with rheumatoid arthritis. J Rheumatol (2009) 36(5):893-897.
24. Tucker WG, Andrew Paskauskas R: The MSMV hypothesis: Measles virus and multiple sclerosis, etiology and treatment. Med Hypotheses (2008) 71(5):682-689.
25. Ohara Y: Multiple sclerosis and measles virus. Jpn J Infect Dis (1999) 52(5):198-200.
26. Cosby SL, McQuaid S, Taylor MJ, Bailey M, Rima BK, Martin SJ, Allen IV: Examination of eight cases of multiple sclerosis and 56 neurological and non-neurological controls for genomic sequences of measles virus, canine distemper virus, simian virus 5 and rubella virus. J Gen Virol (1989) 70 (Pt 8) :2027-2036.
27. Ledford H: Viruses found in lung tumours. Nature Publishing Group, London, UK (2008). www.nature.com/news/2008/080425/full/news.2008.779.html
28. Benharroch D, Shemer-Avni Y, Myint YY, Levy A, Mejirovsky E, Suprun I, Shendler Y, Prinsloo I, Ariad S, Rager-Zisman B, Sacks M et al: Measles virus: Evidence of an association with Hodgkin's disease. Br J Cancer (2004) 91(3):572-579.
29. Benharroch D, Shemer-Avni Y, Levy A, Myint YY, Ariad S, Rager B, Sacks M, Gopas J: New candidate virus in association with Hodgkin's disease. Leuk Lymphoma (2003) 44(4):605-610.
30. Orenstein WA, Strebel PM, Papania M, Sutter RW, Bellini WJ, Cochi SL: Measles eradication: Is it in our future? Am J Public Health (2000) 90(10):1521-1525. • Excellent early discussion of the feasibliy of the global eradication of MV.
31. Centers for Disease Control and Prevention (CDC): Update: Global measles control and mortality reduction - Worldwide, 1991-2001. MMWR Morb Mortal Wkly Rep (2003) 52(20):471-475.
32. No authors listed: From the Centers for Disease Control and Prevention: Progress in global measles control and mortality reduction, 2000-2006. J Am Med Assoc (2008) 299(4):400-402.
33. de Quadros CA, Andrus JK, Danovaro-Holliday MC, Castillo-Solorzano C: Feasibility of global measles eradication after interruption of transmission in the Americas. Expert Rev Vaccines (2008) 7(3):355-362.
34. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, Hersh BS: Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet (2007) 369 (9557):191-200.
35. Centers for Disease Control and Prevention (CDC): Update: Measles - United States, January-July 2008. MMWR Morb Mortal Wkly Rep (2008) 57(33):893-896.
36. Kremer JR, Muller CP: Measles in Europe - there is room for improvement. Lancet (2009) 373 (9661):356-358.
37. Measles surveillance first quarterly report 2008. EUVAC. NET, Copenhagen, Denmark (2008). www.euvac.net/graphics/euvac/pdf/2008-first.pdf
38. Measles surveillance second quarterly report 2008. EUVAC. NET, Copenhagen, Denmark (2008). www.euvac.net/graphics/euvac/pdf/2008-second.pdf
39. Confirmedmeasles cases in England and Wales - an update to the end of October 2008. Health Protection Report. Health Protection Agency, London, UK (2008). www.hpa.org.uk/hpr/archives/2008/news4808.htm#measles
40. Muscat M, Bang H, Wohlfahrt J, Glismann S, Mølbak K: Measles in Europe: An epidemiological assessment. Lancet (2009) 373 (9661):383-389.
41. No authors listed: Measles once again endemic in the United Kingdom. Eurosurveillance (2008) 13(27):3.
42. Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A et al: Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet (1998) 351 (9103):637-641.
43. Madsen KM, Hviid A, Vestergaard M, Schendel D, Wohlfahrt J, Thorsen P, Olsen J, Melbye M: A population-based study of measles, mumps, and rubella vaccination and autism. N Engl J Med (2002) 347(19):1477-1482.
44. DeStefano F, Thompson WW: MMR vaccine and autism: An update of the scientific evidence. Expert Rev Vaccines (2004) 3(1):19-22.
45. Murch SH, Anthony A, Casson DH, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Valentine A, Davies SE, Walker-Smith JA: Retraction of an interpretation. Lancet (2004) 363 (9411):750.
46. Meissner HC, Strebel PM, Orenstein WA: Measles vaccines and the potential for worldwide eradication of measles. Pediatrics (2004) 114(4):1065-1069.
47. Gay NJ: The theory of measles elimination: Implications for the design of elimination strategies. J Infect Dis (2004) 189 (Suppl 1):S27-S35.
48. Watson JC, Hadler SC, Dykewicz CA, Reef S, Phillips L: Measles, mumps, and rubella - Vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep (1998) 47 (RR-8) :1-57.
49. de Quadros CA, Olivé JM, Hersh BS, Strassburg MA, Henderson DA, Brandling-Bennett D, Alleyne GA: Measles elimination in the Americas. Evolving strategies. J Am Med Assoc (1996) 275(3):224-229.
50. Henao-Restrepo AM, Strebel P, John Hoekstra E, Birmingham M, Bilous J: Experience in global measles control, 1990-2001. J Infect Dis (2003) 187 (Suppl 1):S15-S21.
51. de Vries RD, Stittelaar KJ, Osterhaus AD, de Swart RL: Measles vaccination: New strategies and formulations. Expert Rev Vaccines (2008) 7(8):1215-1223. • Overview of goals and strategies for improved measles vaccines.
52. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y: Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. J Am Med Assoc (1998) 280(6):527- 532.
53. Griffin DE, Pan CH: Measles: Old vaccines, new vaccines. Curr Top Microbiol Immunol (2009) 330:191-212. • Overview of goals and strategies for improved vaccines for MV.
54. Pütz MM, Bouche FB, de Swart RL, Muller CP: Experimental vaccines against measles in a world of changing epidemiology. Int J Parasitol (2003) 33 (5-6) :525-545.
55. Mossong J, Nokes DJ, Edmunds WJ, Cox MJ, Ratnam S, Muller CP: Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity. Am J Epidemiol (1999) 150(11):1238-1249.
56. Mossong J, O'Callaghan CJ, Ratnam S: Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population. Vaccine (2000) 19 (4-5) :523-529.
57. Guris D, McCready J, Watson JC, Atkinson WL, Heath JL, Bellini WJ, Polloi A: Measles vaccine effectiveness and duration of vaccine-induced immunity in the absence of boosting from exposure to measles virus. Pediatr Infect Dis J (1996) 15(12):1082-1086.
58. Markowitz LE, Preblud SR, Fine PE, Orenstein WA: Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J (1990) 9(2):101-110.
59. Fernandez H, Banks G, Smith R: Ribavirin: A clinical overview. Eur J Epidemiol (1986) 2(1):1-14.
60. Stogner SW, King JW, Black-Payne C, Bocchini J: Ribavirin and intravenous immune globulin therapy for measles pneumonia in HIV infection. South Med J (1993) 86(12): 1415-1418.
61. Gururangan S, Stevens RF, Morris DJ: Ribavirin response in measles pneumonia. J Infect (1990) 20(3):219-221.
62. Pan American Health Organization: Measles Eradication: Field Guide. Pan American Health Organization, Washington, DC, USA (1999).
63. Moss WJ, Cutts F, Griffin DE: Implications of the human immunodeficiency virus epidemic for control and eradication of measles. Clin Infect Dis (1999) 29(1):106-112.
64. Permar SR, Moss WJ, Ryon JJ, Monze M, Cutts F, Quinn TC, Griffin DE: Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction. J Infect Dis (2001) 183(4):532-538.
65. Roberts L: Polio eradication. Looking for a little luck. Science (2009) 323 (5915):702-705.
66. Katz SL: Polio - new challenges in 2006. J Clin Virol (2006) 36(3):163-165.
67. History and epidemiology of global smallpox eradication. Centers for Disease Control and Prevention, Atlanta, GA, USA (2009). www.bt.cdc.gov/agent/smallpox/training/overview/pdf/eradicationhistory.pdf
68. Lecciones JA, Abejar NH, Dimaano EE, Bartolome R, Cinco S, Mariano N, Yerro ME, Cobar S, Fuggan B: A pilot double-blind, randomized, and placebo-controlled study of orally administered IFN-α-n1 (Ins) in pediatric patients with measles. J Interferon Cytokine Res (1998) 18(9):647-652.
69. Gascon GG: Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-α in subacute sclerosing panencephalitis (SSPE): International multicenter study. J Child Neurol (2003) 18(12):819-827.
70. Hosoya M: Therapy and prognosis in subacute sclerosing panencephalitis. Nippon Rinsho (2007) 65(8):1483-1486.
71. Miyazaki M, Nishimura M, Toda Y, Saijo T, Mori K, Kuroda Y: Long-term follow-up of a patient with subacute sclerosing panencephalitis successfully treated with intrathecal interferon α. Brain Dev (2005) 27(4):301-303.
72. Hara S, Kimura H, Hoshino Y, Hayashi N, Negoro T, Okumura A, Kajita Y, Sakuma T, Nakayama T, Hosoya M, Tomoda A et al: Combination therapy with intraventricular interferon-α and ribavirin for subacute sclerosing panencephalitis and monitoring measles virus RNA by quantitative PCR assay. Brain Dev (2003) 25(5):367-369.
73. del Toro-Riera M, Macaya-Ruiz A, Raspall-Chaure M, Tallada-Serra M, Pasqual-López I, Roig-Quilis M: Subacute sclerosing panencephalitis: Combined treatment with interferon α and intraventricular ribavirin. Rev Neurol (2006) 42(5):277-281.
74. Campbell C, Levin S, Humphreys P, Walop W, Brannan R: Subacute sclerosing panencephalitis: Results of the Canadian Paediatric Surveillance Program and review of the literature. BMC Pediatr (2005) 5:47.
75. Oshiro S, Minema H, Shiroma N, Hirayasu K, Nakada Y: Five patients with subacute sclerosing panencephalitis treated with intraventricular α-interferon and inosinpranobex. No To Hattatsu (2004) 36(1):70-74.
76. Gagnon A, Bouchard RW: Fulminating adult-onset subacute sclerosing panencephalitis in a 49-year-old man. Arch Neurol (2003) 60(8):1160-1161.
77. Tomoda A, Nomura K, Shiraishi S, Miike T, Hamada A, Hosoya M: Trial of intraventricular ribavirin and interferon-α combination therapy for subacute sclerosing panencephalitis (SSPE) in Japan. No To Hattatsu (2003) 35(4):321-326.
78. Forni AL, Schluger NW, Roberts RB: Severe measles pneumonitis in adults: Evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis (1994) 19(3):454-462.
79. Manns MP, Wedemeyer H, Cornberg M: Treating viral hepatitis C: Efficacy, side effects, and complications. Gut (2006) 55(9):1350-1359.
80. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: PEGinterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet (2001) 358 (9286): 958-965.
81. Barclay AJ, Foster A, Sommer A: Vitamin A supplements and mortality related to measles: A randomised clinical trial. Br Med J (Clin Res Ed) (1987) 294 (6567):294-296.
82. D'Souza RM, D'Souza R: Vitamin A for treating measles in children. Cochrane Database Syst Rev (2002) (1) :CD001479.
83. Villamor E, Fawzi WW: Vitamin A supplementation: Implications for morbidity and mortality in children. J Infect Dis (2000) 182 (Suppl 1):S122-S133.
84. Wyde PR: Chemotherapy of respiratory viruses: Prospects and challenges. Drug Resist Updat (1999) 2(4):244-258.
85. Koschel K, Brinckmann U, Hoyningen-Huene VV: Measles virus antisense sequences specifically cure cells persistently infected with measles virus. Virology (1995) 207(1):168-178.
86. Bell AF, Whitton JL, Fujinami RS: Antisense-mediated resistance to measles virus infection in HeLa cells. J Infect Dis (1997) 176(1):258-261.
87. Sleeman K, Stein DA, Tamin A, Reddish M, Iversen PL, Rota PA: Inhibition of measles virus infections in cell cultures by peptide-conjugated morpholino oligomers. Virus Res (2009) 140 (1-2) :49-56.
88. Miller FA, Dixon GJ, Arnett G, Dice JR, Rightsel WA, Schabel FM Jr, McLean IW Jr: Antiviral activity of carbobenzosy di-and tripeptides on measles virus. Appl Microbiol (1968) 16(10): 1489-1496.
89. Nicolaides E, DeWald H, Lipnik M, Westland R, Posler J: Potential antiviral agents. Carbobenzoxy di-and tripeptides active against measles and herpes viruses. J Med Chem (1968) 11(1):74-79.
90. Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr: Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proc Natl Acad Sci USA (1996) 93(5):2186-2191. • Identification of peptidic inhibitors against different paramyxoviruses.
91. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T et al: Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry Nat Med (1998) 4(11):1302-1307. • Demonstration of efficacy of peptidic (heptad repeat-derived) inhibitors of HIV.
92. Kilby JM, Lalezari JP, Eron JJ, Carlson M, Cohen C, Arduino RC, Goodgame JC, Gallant JE, Volberding P, Murphy RL, Valentine F et al: The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses (2002) 18(10):685-693.
93. Jamjian MC, McNicholl IR: Enfuvirtide: First fusion inhibitor for treatment of HIV infection. Am J Health Syst Pharm (2004) 61(12):1242-1247.
94. Parker ME, Chabot S, Ward BJ, Johns T: Traditional dietary additives of the Maasai are antiviral against the measles virus. J Ethnopharmacol (2007) 114(2):146-152.
95. Petricevich VL, Mendonça RZ: Inhibitory potential of Crotalus durissus terrificus venom on measles virus growth. Toxicon (2003) 42(2):143-153.
96. Wachsman MB, Ramirez JA, Galagovsky LR, Coto CE: Antiviral activity of brassinosteroids derivatives against measles virus in cell cultures. Antivir Chem Chemother (2002) 13(1): 61-66.
97. Olila D, Olwa O, Opuda-Asibo J: Screening extracts of Zanthoxylum chalybeum and Warburgia ugandensis for activity against measles virus (Swartz and Edmonston strains) in vitro. Afr Health Sci (2002) 2(1):2-10.
98. Cos P, Hermans N, De Bruyne T, Apers S, Sindambiwe JB, Vanden Berghe D, Pieters L, Vlietinck AJ: Further evaluation of Rwandan medicinal plant extracts for their antimicrobial and antiviral activities. J Ethnopharmacol (2002) 79(2):155-163.
99. Huang SP, Shieh GJ, Lee L, Teng HJ, Kao ST, Lin JG: Inhibition effect of shengma-gegen-tang on measles virus in Vero cells and human peripheral blood mononuclear cells. Am J Chin Med (1997) 25(1):89-96.
100. McWhorter JH: Spicebush. A Cherokee remedy for the measles. N C Med J (1996) 57(5):306.
101. Lin YM, Flavin MT, Schure R, Chen FC, Sidwell R, Barnard DL, Huffman JH, Kern ER: Antiviral activities of biflavonoids. Planta Med (1999) 65(2):120-125.
102. Kurokawa M, Ochiai H, Nagasaka K, Neki M, Xu H, Kadota S, Sutardjo S, Matsumoto T, Namba T, Shiraki K: Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antiviral Res (1993) 22 (2-3) :175-188.
103. Hayashi T, Hayashi K, Maeda M, Kojima I: Calcium spirulan, an inhibitor of enveloped virus replication, from a blue-green alga Spirulina platensis. J Nat Prod (1996) 59(1):83-87.
104. Barnard DL: Inhibitors of measles virus. Antivir Chem Chemother (2004) 15(3):111-119. • Comprehensive review of experimental MV inhibitors.
105. White LK, Yoon JJ, Lee JK, Sun A, Du Y, Fu H, Snyder JP, Plemper RK: Nonnucleoside inhibitor of measles virus RNA-dependent RNA polymerase complex activity. Antimicrob Agents Chemother (2007) 51(7):2293-2303. • First report of a highly potent small-molecule MV RdRp inhibitor class.
106. Sun A, Chandrakumar N, Yoon JJ, Plemper RK, Snyder JP: Nonnucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex activity: Synthesis and in vitro evaluation. Bioorg Med Chem Lett (2007) 17(18):5199-5203.
107. Offit PA (Ed): Autism's False Prophets. Bad Science, Risky Medicine and the Search for a Cure. Columbia University Press, New York, NY, USA (2008).
108. Shuto S, Obara T, Toriya M, Hosoya M, Snoeck R, Andrei G, Balzarini J, De Clercq E: New neplanocin analogues. 1. Synthesis of 6'-modified neplanocin A derivatives as broad-spectrum antiviral agents. J Med Chem (1992) 35(2): 324-331.
109. Shigeta S, Mori S, Baba M, Ito M, Honzumi K, Nakamura K, Oshitani H, Numazaki Y, Matsuda A, Obara T et al: Antiviral activities of ribavirin, 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide, and 6'-(R)-6'-C-methylneplanocin A against several ortho-and paramyxoviruses. Antimicrob Agents Chemother (1992) 36(2):435-439.
110. Patil SD, Schneller SW, Hosoya M, Snoeck R, Andrei G, Balzarini J, De Clercq E: Synthesis and antiviral properties of (±)-5'- noraristeromycin and related purine carbocyclic nucleosides. A new lead for anti-human cytomegalovirus agent design. J Med Chem (1992) 35(18):3372-3377.
111. Siddiqi SM, Chen X, Rao J, Schneller SW, Ikeda S, Snoeck R, Andrei G, Balzarini J, De Clercq E: 3-deaza-and 7-deaza-5'-noraristeromycin and their antiviral properties. J Med Chem (1995) 38(6):1035-1038.
112. Barnard DL, Stowell VD, Seley KL, Hegde VR, Das SR, Rajappan VP, Schneller SW, Smee DF, Sidwell RW: Inhibition of measles virus replication by 5'-nor carbocyclic adenosine analogues. Antivir Chem Chemother (2001) 12(4):241-250.
113. Li W, Yin X, Schneller SW: 5'-Fluoro-5'-deoxyaristeromycin. Bioorg Med Chem Lett (2008) 18(1):220-222.
114. Wyde PR, Moore-Poveda DK, De Clercq E, Neyts J, Matsuda A, Minakawa N, Guzman E, Gilbert BE: Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections. Antimicrob Agents Chemother (2000) 44(5): 1146-1152.
115. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE: The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med (2000) 6(12):1375-1379.
116. Kosugi Y, Saito Y, Mori S, Watanabe J, Baba M, Shigeta S: Antiviral activies of mizoribine and other inosine monophosphate dehydrogenase inhibitors against several ortho-and paramyxoviruses. Antivir. Chemother (1994) 5(6):366-371.
117. Zhang N, Chen HM, Sood R, Kalicharran K, Fattom AI, Naso RB, Barnard DL, Sidwell RW, Hosmane RS: In vitro inhibition of the measles virus by novel ring-expanded ('fat') nucleoside analogues containing the imidazo[4, 5-e]diazepine ring system. Bioorg Med Chem Lett (2002) 12(23):3391-3394.
118. Barnard DL, Xu ZQ, Stowell VD, Yuan H, Smee DF, Samy R, Sidwell RW, Nielsen MK, Sun L, Cao H, Li A et al: Coumarins and pyranocoumarins, potential novel pharmacophores for inhibition of measles virus replication. Antivir Chem Chemother (2002) 13(1):39-59.
119. Wyde PR, Moore DK, Pimentel DM, Blough HA: Evaluation of the antiviral activity of N-(phosphonoacetyl)-1-aspartate against paramyxoviruses in tissue culture and against respiratory syncytial virus in cotton rats. Antiviral Res (1995) 27 (1-2): 59-69.
120. Santagati NA, Bousquet E, Garozzo A, Prezzavento O, Spadaro A, Ronsisvalle G: Synthesis and anti-measles virus activity of new isoquinolin-4-one derivatives. Farmaco (2003) 58(12):1217- 1225.
121. Plemper RK, Doyle J, Sun A, Prussia A, Cheng LT, Rota PA, Liotta DC, Snyder JP, Compans RW: Design of a small-molecule entry inhibitor with activity against primary measles virus strains. Antimicrob Agents Chemother (2005) 49(9):3755-3761.
122. Plemper RK, Erlandson KJ, Lakdawala AS, Sun A, Prussia A, Boonsombat J, Aki-Sener E, Yalcin I, Yildiz I, Temiz-Arpaci O, Tekiner B et al: A target site for template-based design of measles virus entry inhibitors. Proc Natl Acad Sci USA (2004) 101(15):5628-5633.
123. Sun A, Prussia A, Zhan W, Murray EE, Doyle J, Cheng LT, Yoon JJ, Radchenko EV, Palyulin VA, Compans RW, Liotta DC et al: Nonpeptide inhibitors of measles virus entry. J Med Chem (2006) 49(17):5080-5092.
124. Garozzo A, Cutri CC, Pannecouque C, Castro A, Guerrera F, De Clercq E: Isothiazole derivatives as antiviral agents. Antivir Chem Chemother (2007) 18(5):277-283.
125. Cutrì CC, Garozzo A, Siracusa MA, Castro A, Tempera G, Sarvà MC, Guerrera F: Synthesis of new 3-methylthio-5-aryl-4- isothiazolecarbonitriles with broad antiviral spectrum. Antiviral Res (2002) 55(2):357-368.
126. Sun A, Yoon JJ, Yin Y, Prussia A, Yang Y, Min J, Plemper RK, Snyder JP: Potent non-nucleoside inhibitors of the measles virus RNA-dependent RNA polymerase complex. J Med Chem (2008) 51(13):3731-3741.